NLS Pharmaceutics Expands CNS Pipeline with AEX-6xx Series, Bolsters Position with Solid Cash Position and Strategic Funding Outlook.

NLS Pharmaceutics has expanded its CNS pipeline with the AEX-6xx series, developed by Aexon Labs. The DOXA platform targets arousal stability, cognition, and neuroprotection. AEX-635 modulates MRP1, enhancing neuroprotective effects and improving CNS drug bioavailability. The company has a solid cash position and strategic funding outlook, with a committed ELOC to support clinical programs. The DOXA platform has shown up to 80% reduction in cataplexy and >70% increase in wakefulness in orexin knockout narcolepsy models.